Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017054484) PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND APPLICATION THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2017/054484 International Application No.: PCT/CN2016/084056
Publication Date: 06.04.2017 International Filing Date: 31.05.2016
IPC:
C07D 471/04 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/55 (2006.01) ,A61K 31/4545 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
4545
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
Applicants:
广州必贝特医药技术有限公司 GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. [CN/CN]; 中国广东省广州市 科学城崖鹰石路25号8楼 25 Yayingshi Road, 8th Floor, Science City, Guangzhou, Guangdong 510660, CN
Inventors:
蔡雄 CAI, Xiong; CN
钱长庚 QIAN, Changgeng; CN
李军旗 LI, Junqi; CN
卿远辉 QING, Yuanhui; CN
王艳艳 WANG, Yanyan; CN
薛伟才 XUE, Weicai; CN
游华金 YOU, Huajin; CN
Agent:
广州华进联合专利商标代理有限公司 ADVANCE CHINA IP LAW OFFICE; 中国广东省广州市 天河区花城大道85号3901房 Room 3901, No. 85 Huacheng Avenue, Tianhe District, Guangzhou, Guangdong 510623, CN
Priority Data:
201510646418.430.09.2015CN
Title (EN) PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND APPLICATION THEREOF
(FR) COMPOSÉ DE PYRIMIDINE OU DE PYRIDOPIRYDINE ET APPLICATION CORRESPONDANTE
(ZH) 嘧啶或吡啶并吡啶酮类化合物及其应用
Abstract:
(EN) The present invention discloses a pyrimidine or pyridopyridone compound as shown in formula (I) and an application thereof relating to the technical field of medicament preparation. The compound can selectively suppress cyclin-dependent kinases (Cdks) CFK4 and CDK6 with almost no suppression of the activity of the kinase CDK2. Thus, the compound can be used for various diseases caused by cell cycle control disorders involving CDK4 and CDK6, and particularly in the treatment of malignant tumors.
(FR) La présente invention concerne un composé de pyrimidine ou de pyridopyridone tel que représenté dans la formule (I) et une application correspondante, concernant le domaine technique de préparation de médicaments. Le composé peut supprimer de manière sélective les kinases cycline-dépendantes (CDK) CDK4 et CDK6 quasiment sans suppression de l'activité de la kinase CDK2. Ainsi, le composé peut être utilisé pour diverses maladies provoquées par des troubles de régulation du cycle cellulaire impliquant CDK4 et CDK6 et particulièrement dans le traitement de tumeurs malignes.
(ZH) 本发明公开了一种式(I)所示的嘧啶或吡啶并吡啶酮类化合物及其应用,属于药物制备技术领域。该类化合物能够选择性的抑制细胞周期依赖性激酶(Cdks)CDK4和CDK6,而对CDK2激酶几乎无抑制活性,因此,该类化合物可用于CDK4和CDK6所参与的细胞周期控制失调导致各种疾病,特别是恶性肿瘤的治疗中。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)